Neurotechnology company Cognito Therapeutics scores $73M

March 23, 2023. 09:52 am. Photo courtesy of Cognito Therapeutics. Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, scored $73 …

CouponFollow Extension

$73
OFF

Neurotechnology Company Cognito Therapeutics Scores $73M

1 week from now

March 23, 2023. 09:52 am. Photo courtesy of Cognito Therapeutics. Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, scored $73 …

mobihealthnews.com

$73
OFF

Cognito Therapeutics Raises $73M Series B To Advance …

1 week from now

Mar 22, 2023 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, …

businesswire.com

$73
OFF

Cognito Therapeutics Scores $73m Series B - Venture Capital Journal

1 week from now

Mar 22, 2023 · The funding will advance Cognito’s study of its non-invasive neuromodulation device. Cambridge, Massachusetts-based Cognito Therapeutics, a neurotechnology company …

venturecapitaljournal.com

$73
OFF

Cognito Therapeutics Raises $73M In Series B Funding - FinSMEs

1 week from now

March 22, 2023. Cognito Therapeutics, a Cambridge, MA-based neurotechnology company advancing disease-modifying therapies to treat CNS diseases, raised $73M in Series B …

finsmes.com

$73
OFF

Cognito Collects $73M For Light-and-sound Alzheimer's Therapy

1 week from now

Mar 22, 2023 · Cognito beams up $73M for study of light-and-sound neuromod therapy to treat Alzheimer's. Riding high on early clinical trial results showing that its neuromodulation headset …

fiercebiotech.com

$73
OFF

Cognito Therapeutics Raises $73M In Series B Funding For …

1 week from now

Mar 23, 2023 · Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, has completed a $73M Series B financing round led by …

mpo-mag.com

$73
OFF

Neurotechnology Company Cognito Therapeutics Scores $73M

1 week from now

Mar 27, 2023 · Neurotechnology Company Cognito Therapeutics Scores $73M. Share: March 27, 2023. Cognito Therapeutics, a Massachusetts-based startup focused on using noninvasive …

distilnfo.com

$73
OFF

Neurotechnology Company Cognito Therapeutics Scores $73M

1 week from now

Apr 3, 2023 · Cognito Therapeutics, a Massachusetts-based startup developing a wearable device using visual and auditory stimulation to treat neurodegenerative disorders, has raised …

distilnfo.com

$73
OFF

Cognito Therapeutics Raises $73M For Non-invasive Neuromod Tech

1 week from now

Mar 22, 2023 · Cognito Therapeutics announced today that it raised $73 million in a Series B financing round to support its neuromodulation technology. Cambridge, Massachusetts–based …

massdevice.com

$73
OFF

Neurotechnology Company Cognito Therapeutics Scores $73M

1 week from now

Mar 23, 2023 · Originally published by MobiHealthNews on March 23, 2023. Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative …

agetech.news

$73
OFF

Cognito Raises $73M For Alzheimer’s Treatment Headset

1 week from now

Mar 22, 2023 · Cognito Raises $73M for Alzheimer’s Treatment Headset. It delivers proprietary gamma frequency light and sound stimulation. Medical Design & Development Staff. Mar 22, …

medicaldesigndevelopment.com

FAQs about Neurotechnology company Cognito Therapeutics scores $73M Coupon?

Does Cognito therapeutics have a series B financing?

CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors. ...

Who is Cognito Therapeutics?

About Cognito Therapeutics Cognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. ...

Is Cognito a non-invasive neuromodulation device?

Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company’s lead therapy is currently in a pivotal study in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. ...

Who will join Cognito's Board of directors?

In addition to the financing, Dr. Rick Kuntz, MD, MSc, former Senior Vice President, Chief Medical and Scientific Officer of Medtronic and Helen Liang, Founder & Managing Partner at FoundersX, will join Cognito’s Board of Directors. Dr. ...

Can a non-drug neuromodulation intervention help treat Alzheimer's & Cognito?

“A non-drug neuromodulation intervention has the potential to better address the complex nature of neurodegenerative diseases such as Alzheimer’s and Cognito is well-positioned to be a leader in this new paradigm,” said Helen Liang, Founder & Managing Partner, FoundersX Ventures. ...